Endocarditis
Endocarditis refers to an inflammatory disease caused by direct invasion of the endocardium by pathogenic microorganisms. The thrombi (warts) formed on the surface of the heart valves contain pathogenic microorganisms.
-
Site of disease:
heart -
Infectious :
Not contagious -
Frequent population:
No special disease group -
Related symptoms:
-
Concurrent disease:
Related Drugs
METRONIDAZOLE- metronidazole_tablet, film coated
Indication: INDICATIONS AND USAGE
Symptomatic Trichomoniasis. T. vaginalis Asymptomatic Trichomoniasis. T. vaginalis Treatment of Asymptomatic Sexual Partners. T. vaginalis Amebiasis In amebic liver abscess, Metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides B. fragilis B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus Clostridium Eubacterium Peptococcus species, Peptostreptococcus SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides B. fragilis Clostridium Peptococcus species, Peptostreptococcus Fusobacterium GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides B. fragilis Clostridium Peptococcus species, Peptostreptococcus Fusobacterium BACTERIAL SEPTICEMIA caused by Bacteroides B. fragilis Clostridium BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides B. fragilis CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides B. fragilis LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides B. fragilis ENDOCARDITIS caused by Bacteroides B. fragilis To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Trichomoniasis:
In the Female: One-day treatment − Seven-day course of treatment − The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other. Pregnant patients should not be treated during the first trimester (see CONTRAINDICATIONS PRECAUTIONS, Pregnancy When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment. In the Male: Treatment should be individualized as it is for the female.
Amebiasis
Adults: For acute intestinal amebiasis (acute amebic dysentery): For amebic liver abscess: Pediatric patients
Anaerobic Bacterial Infections
In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially. The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period. The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.
Symptomatic Trichomoniasis. T. vaginalis Asymptomatic Trichomoniasis. T. vaginalis Treatment of Asymptomatic Sexual Partners. T. vaginalis Amebiasis In amebic liver abscess, Metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides B. fragilis B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus Clostridium Eubacterium Peptococcus species, Peptostreptococcus SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides B. fragilis Clostridium Peptococcus species, Peptostreptococcus Fusobacterium GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides B. fragilis Clostridium Peptococcus species, Peptostreptococcus Fusobacterium BACTERIAL SEPTICEMIA caused by Bacteroides B. fragilis Clostridium BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides B. fragilis CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides B. fragilis LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides B. fragilis ENDOCARDITIS caused by Bacteroides B. fragilis To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Trichomoniasis:
In the Female: One-day treatment − Seven-day course of treatment − The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other. Pregnant patients should not be treated during the first trimester (see CONTRAINDICATIONS PRECAUTIONS, Pregnancy When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment. In the Male: Treatment should be individualized as it is for the female.
Amebiasis
Adults: For acute intestinal amebiasis (acute amebic dysentery): For amebic liver abscess: Pediatric patients
Anaerobic Bacterial Infections
In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially. The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period. The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.
Manufacturer:
Redpharm Drug
AMPICILLIN- ampicillin sodium_injection, powder, for solution
Indication: INDICATIONS AND USAGE
Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections Streptococcus pneumoniae, Staphylococcus aureus H. influenzae Bacterial Meningitis E. coli, Listeria monocytogenes, N. meningitidis Septicemia and Endocarditis Streptococcus E. coli, Proteus mirabilis Salmonella Urinary Tract Infections E. coli Proteus mirabilis Gastrointestinal Infections Salmonella typhi Salmonella Shigella Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.
Bacterial Meningitis
Adults and children - Neonates (less than or equal to 28 days of postnatal age) Table 1 Table 1: Dosage in Neonates (less than or equal to 28 days of postnatal age) for Bacterial Meningitis and Septicemia Gestational age (weeks) Postnatal age (days) Dosage less than or equal to 34 less than or equal to 7 100 mg/kg/day in equally divided doses every 12 hours.
Septicemia
Adults and children - Neonates (less than or equal to 28 days of postnatal age) - Table 1 Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10 days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections Streptococcus pneumoniae, Staphylococcus aureus H. influenzae Bacterial Meningitis E. coli, Listeria monocytogenes, N. meningitidis Septicemia and Endocarditis Streptococcus E. coli, Proteus mirabilis Salmonella Urinary Tract Infections E. coli Proteus mirabilis Gastrointestinal Infections Salmonella typhi Salmonella Shigella Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.
Bacterial Meningitis
Adults and children - Neonates (less than or equal to 28 days of postnatal age) Table 1 Table 1: Dosage in Neonates (less than or equal to 28 days of postnatal age) for Bacterial Meningitis and Septicemia Gestational age (weeks) Postnatal age (days) Dosage less than or equal to 34 less than or equal to 7 100 mg/kg/day in equally divided doses every 12 hours.
Septicemia
Adults and children - Neonates (less than or equal to 28 days of postnatal age) - Table 1 Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10 days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Manufacturer:
Medical Purchasing Solutions, LLC
AMPICILLIN- ampicillin sodium_injection, powder, for solution
Indication: INDICATIONS AND USAGE
Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections Streptococcus pneumoniae, Staphylococcus aureus H. influenzae Bacterial Meningitis E. coli, Listeria monocytogenes, N. meningitidis Septicemia and Endocarditis Streptococcus E. coli, Proteus mirabilis Salmonella Urinary Tract Infections E. coli Proteus mirabilis Gastrointestinal Infections Salmonella typhi Salmonella Shigella Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.
Bacterial Meningitis
Adults and children - Neonates (less than or equal to 28 days of postnatal age) Table 1 Table 1: Dosage in Neonates (less than or equal to 28 days of postnatal age) for Bacterial Meningitis and Septicemia Gestational age (weeks) Postnatal age (days) Dosage less than or equal to 34 less than or equal to 7 100 mg/kg/day in equally divided doses every 12 hours.
Septicemia
Adults and children - Neonates (less than or equal to 28 days of postnatal age) - Table 1 Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10 days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections Streptococcus pneumoniae, Staphylococcus aureus H. influenzae Bacterial Meningitis E. coli, Listeria monocytogenes, N. meningitidis Septicemia and Endocarditis Streptococcus E. coli, Proteus mirabilis Salmonella Urinary Tract Infections E. coli Proteus mirabilis Gastrointestinal Infections Salmonella typhi Salmonella Shigella Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.
Bacterial Meningitis
Adults and children - Neonates (less than or equal to 28 days of postnatal age) Table 1 Table 1: Dosage in Neonates (less than or equal to 28 days of postnatal age) for Bacterial Meningitis and Septicemia Gestational age (weeks) Postnatal age (days) Dosage less than or equal to 34 less than or equal to 7 100 mg/kg/day in equally divided doses every 12 hours.
Septicemia
Adults and children - Neonates (less than or equal to 28 days of postnatal age) - Table 1 Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10 days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis.
Manufacturer:
Medical Purchasing Solutions, LLC
METRONIDAZOLE- metronidazole_injection, solution
Indication: Treatment of Anaerobic Infections Metronidazole Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. Metronidazole is effective in Bacteroides fragilis Intra-abdominal Infections Bacteroides B. fragilis B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus Clostridium Eubacterium Peptococcus Peptostreptococcus Skin and Skin Structure Infections Bacteroides B. fragilis Clostridium Peptococcus Peptostreptococcus Fusobacterium Gynecologic Infections Bacteroides B. fragilis Clostridium Peptococcus Peptostreptococcus Fusobacterium Bacterial Septicemia Bacteroides B. fragilis Clostridium Bone and Joint Infections Bacteroides B. fragilis Central Nervous System (CNS) Infections Bacteroides B. fragilis Lower Respiratory Tract Infections Bacteroides B. fragilis Endocarditis Bacteroides B. fragilis Prophylaxis The prophylactic administration of Metronidazole Injection, USP preoperatively, intraoperatively, and postoperatively may reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection, USP should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Manufacturer:
Hospira, Inc.
METRONIDAZOLE- metronidazole_tablet, film coated
Indication: INDICATIONS AND USAGE
Symptomatic Trichomoniasis. T. vaginalis Asymptomatic Trichomoniasis. T. vaginalis Treatment of Asymptomatic Sexual Partners. T. vaginalis Amebiasis In amebic liver abscess, Metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides B. fragilis B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus Clostridium Eubacterium Peptococcus species, Peptostreptococcus SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides B. fragilis Clostridium Peptococcus species, Peptostreptococcus Fusobacterium GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides B. fragilis Clostridium Peptococcus species, Peptostreptococcus Fusobacterium BACTERIAL SEPTICEMIA caused by Bacteroides B. fragilis Clostridium BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides B. fragilis CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides B. fragilis LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides B. fragilis ENDOCARDITIS caused by Bacteroides B. fragilis To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Trichomoniasis:
In the Female: One-day treatment − Seven-day course of treatment − The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other. Pregnant patients should not be treated during the first trimester (see CONTRAINDICATIONS PRECAUTIONS, Pregnancy When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment. In the Male: Treatment should be individualized as it is for the female.
Amebiasis
Adults: For acute intestinal amebiasis (acute amebic dysentery): For amebic liver abscess: Pediatric patients
Anaerobic Bacterial Infections
In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially. The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period. The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.
Symptomatic Trichomoniasis. T. vaginalis Asymptomatic Trichomoniasis. T. vaginalis Treatment of Asymptomatic Sexual Partners. T. vaginalis Amebiasis In amebic liver abscess, Metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides B. fragilis B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus Clostridium Eubacterium Peptococcus species, Peptostreptococcus SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides B. fragilis Clostridium Peptococcus species, Peptostreptococcus Fusobacterium GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides B. fragilis Clostridium Peptococcus species, Peptostreptococcus Fusobacterium BACTERIAL SEPTICEMIA caused by Bacteroides B. fragilis Clostridium BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides B. fragilis CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides B. fragilis LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides B. fragilis ENDOCARDITIS caused by Bacteroides B. fragilis To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Trichomoniasis:
In the Female: One-day treatment − Seven-day course of treatment − The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other. Pregnant patients should not be treated during the first trimester (see CONTRAINDICATIONS PRECAUTIONS, Pregnancy When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment. In the Male: Treatment should be individualized as it is for the female.
Amebiasis
Adults: For acute intestinal amebiasis (acute amebic dysentery): For amebic liver abscess: Pediatric patients
Anaerobic Bacterial Infections
In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially. The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period. The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.
Manufacturer:
REMEDYREPACK INC.
METRONIDAZOLE- metronidazole_injection, solution
Indication: Treatment of Anaerobic Infections Metronidazole Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. Metronidazole is effective in Bacteroides fragilis Intra-abdominal Infections Bacteroides B. fragilis ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus Clostridium Eubacterium Peptococcus Peptostreptococcus Skin and Skin Structure Infections Bacteroides B. fragilis Clostridium Peptococcus Peptostreptococcus Fusobacterium Gynecologic Infections Bacteroides B. fragilis Clostridium Peptococcus Peptostreptococcus Fusobacterium Bacterial Septicemia Bacteroides B. fragilis Clostridium Bone and Joint Infections Bacteroides B. fragilis Central Nervous System (CNS) Infections Bacteroides B. fragilis Lower Respiratory Tract Infections Bacteroides B. fragilis Endocarditis Bacteroides B. fragilis Prophylaxis The prophylactic administration of Metronidazole Injection, USP preoperatively, intraoperatively, and postoperatively may reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection, USP should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Manufacturer:
Hospira, Inc.
CEFAZOLIN- cefazolin_injection, powder, for solution
Indication: Cefazolin for Injection, USP is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections: S. pneumoniae, Klebsiella , H. influenzae, S. aureus . Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for Injection, USP in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections: E. coli, P. mirabilis, Klebsiella . Skin and Skin Structure Infections: S. aureus Biliary Tract Infections: E. coli, P. mirabilis, Klebsiella S. aureus. Bone and Joint Infections: S. aureus. Genital Infections: E. coli, P. mirabilis, Klebsiella . Septicemia: S. pneumoniae, S. aureus P. mirabilis, E. coli, Klebsiella Endocarditis: S. aureus . Perioperative Prophylaxis: The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection, USP should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted. (See DOSAGE AND ADMINISTRATION To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Manufacturer:
REMEDYREPACK INC.
METRONIDAZOLE- metronidazole_tablet
Indication: Symptomatic Trichomoniasis. T. vaginalis Asymptomatic Trichomoniasis. T. vaginalis Treatment of Asymptomatic Sexual Partners. T. vaginalis Amebiasis. In amebic liver abscess, METRONIDAZOLE, USP therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides B. fragilis B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus Clostridium Eubacterium Peptococcus Peptostreptococcus SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides B. fragilis Clostridium Peptococcus Peptostreptococcus Fusobacterium GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides B. fragilis Clostridium Peptococcus Peptostreptococcus Fusobacterium BACTERIAL SEPTICEMIA caused by Bacteroides B. fragilis Clostridium BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides B. fragilis CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides B. fragilis LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides B. fragilis ENDOCARDITIS caused by Bacteroides B. fragilis To reduce the development of drug-resistant bacteria and maintain the effectiveness of METRONIDAZOLE, USP and other antibacterial drugs, METRONIDAZOLE, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Manufacturer:
Rising Pharma Holdings, Inc.
CEFAZOLIN- cefazolin_injection, powder, for solution
Indication: Cefazolin for Injection, USP is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections: S. pneumoniae, Klebsiella , H. influenzae, S. aureus . Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for Injection, USP in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections: E. coli, P. mirabilis, Klebsiella . Skin and Skin Structure Infections: S. aureus Biliary Tract Infections: E. coli, P. mirabilis, Klebsiella S. aureus. Bone and Joint Infections: S. aureus. Genital Infections: E. coli, P. mirabilis, Klebsiella . Septicemia: S. pneumoniae, S. aureus P. mirabilis, E. coli, Klebsiella Endocarditis: S. aureus . Perioperative Prophylaxis: The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection, USP should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted. (See DOSAGE AND ADMINISTRATION To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Manufacturer:
REMEDYREPACK INC.